Endocrine Abstracts

Introduction: Treatment with recombinant ST is subject to strict criteria. Differences in the response to therapy based on the maximum level of ST in diagnostic tests (ST ≤5 vs ST >5 ng/ml), could predict whose patients would benefit more from therapy.

Purpase: Assess differences in the response to therapy with rST in patients with IDGH.

Methods: Selected 18 patients with IDGH followed by Endocrinology. Anthropometric (height (H), weight, growth velocity (GV), target height (TH)), analytical (IGF1, IGFBP3) and imaging (bone age (BA)) data were collected before, and 12 months after treatment. Two groups were formed based in ST levels obtained in the stimulation tests, ST≤5 ng/ml (n=9) and ST>5 ng/ml.

Results: The sample (male n=13) presented chronological age (CA) of 8.6±3.5 years, H 114.3±18.6 cm (z-score −2.7±0.6), BMI 17.3±3.1 kg/m²; TH 165.4±7.3 cm; BA 5.8±3.5 years; GV 4.0±0.8 cm/year; IGF1 104.7±70.1 ng/ml, IGFBP3 2.8±1.3 mg/ml. After 12 months of therapy there was a significant increase in GV (8.1±2.0, P<0.001) and H (123.9±19.2, P<0.001; z-score −2.0±0.9). When comparing both groups, there was a difference in ST levels after stimulation tests (3.4±1.8 vs 5.9±1.1 ng/ml, P=0.03). There were no other differences between the two groups when comparing for dose of rST (0.035±0.008 vs 0.035±0.005 mg/kg per day, P=0.867), anthropometric (H 114.4±21.2 vs 114.1±16.9 cm, P=0.98; GV 3.8±0.7 vs 4.2±0.9 cm/year, P=0.28), analytical (IGF1 104.1±77.1 vs 105.3±68.1 ng/ml, P=0.97) or imaging (BA 5.9±3.9 vs 5.7±3.2 years; P=0.90) parameters before treatment. The same was observed 12 months after therapy (ST dose 0.031±0.008 vs 0.029±0.004 mg/kg per day, P=0.42; H 124.4±22.2 vs 123.5±16.6 cm, P=0.93; GV 8.5±2.5 vs 7.7±1.4 cm/year, P=0.44; IGF1 258.8±243.4 vs 309.6±191.4 ng/ml, P=0.63).

Conclusion: Response to therapy with rST in children with IDGH is similar in cases of severe and in cases of partial deficit.